- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Design considerations for early-phase clinical trials of immune-oncology agents ; volume:6 ; number:1 ; day:22 ; month:8 ; year:2018 ; pages:1-10 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (22.8.2018), 1-10, 12.2018
- Creator
-
Wages, Nolan A.
- Contributor
-
Chiuzan, Cody
Panageas, Katherine S.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0389-8
- URN
-
urn:nbn:de:101:1-2018101620553299790461
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wages, Nolan A.
- Chiuzan, Cody
- Panageas, Katherine S.
- SpringerLink (Online service)
Other Objects (12)
Clinical trials in oncology
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
Phase I Clinical Trials in Oncology
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
Immune oncology, immune responsiveness and the theory of everything
Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Immune modulation by infectious agents
Umbrella and basket trials in oncology: ethical challenges
Clinical trials in oncology
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
Phase I Clinical Trials in Oncology
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
Immune oncology, immune responsiveness and the theory of everything
Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Immune modulation by infectious agents
Umbrella and basket trials in oncology: ethical challenges
Clinical trials in oncology
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
Phase I Clinical Trials in Oncology
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
Immune oncology, immune responsiveness and the theory of everything
Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Immune modulation by infectious agents